Article Text

AB0736 Strategy for the Early Detection and Referral of Patients with Suspected Spondyloarthritis
  1. X. Juanola1,
  2. E. Collantes2,
  3. F. Leόn3,
  4. A. Torres4,
  5. M.J. García de Yébenes5,
  6. R. Queiro6,
  7. J. Gratacόs7,
  8. E. García Criado8,
  9. S. Giménez9,
  10. L. Carmona5
  11. on behalf of Grupo de Estudio para el Dolor Lumbar Inflamatorio
  1. 1Rheumatology, Hospital Universitari de Bellvitge, Barcelona
  2. 2Rheumatology, IMIBIC, Cόrdoba
  3. 3CS Universitario San Juan de la Cruz, Pozuelo de Alarcόn
  4. 4CS Arroyo de la Media Legua
  5. 5InMusc, Madrid
  6. 6Rheumatology, HU Central de Asturias, Oviedo
  7. 7Rheumatology, H Parc Taulí, Sabadell
  8. 8UGC Fuensanta, Cόrdoba
  9. 9UGC Limonar, Málaga, Spain


Objectives To design a strategy for early detection and referral of patients with suspected spondyloarthritis (SpA) by primary care physicians (PCP).

Methods We used a modified RAND/UCLA methodology and systematic review (SR). A discussion group, formed by rheumatologists and PCP, discussed the process map and proposed recommendations and algorithms. These, together with the results of the SR, underwent 2 Delphi rounds to assess acceptance by a large group of users.

Results The recommendations and grade of agreement are presnted in Table 1).

Table 1

Conclusions Any chronic (>3 months) LBP in <45 years patients should be investigated in 4 phases 1) key questions, 2) extra questions, 3) physical examination, and 4) additional tests. They should be referred to rheumatology if having 1) IBP, 2) signs suggestive of SpA, or 3) HLA B27+, elevated CRP, or sacroiliitis. Recommendations on the referral process are included.

Acknowledgements This project was supported by a grant from MSD.

Disclosure of Interest X. Juanola: None declared, E. Collantes: None declared, F. Leόn: None declared, A. Torres: None declared, M. J. García de Yébenes: None declared, R. Queiro: None declared, J. Gratacόs: None declared, E. García Criado: None declared, S. Giménez: None declared, L. Carmona Grant/research support: Abbvie, MSD, Roche, Speakers bureau: Roche, Pfizer

DOI 10.1136/annrheumdis-2014-eular.1812

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.